Propranolol in the Treatment of MigraineBr Med J 1974; 2 doi: https://doi.org/10.1136/bmj.2.5921.699 (Published 29 June 1974) Cite this as: Br Med J 1974;2:699
- Tor-Erik Widerøe,
- Tor Vigander
Beta-blocking drugs that prevent cranial vasodilatation are potentially valuable in the prophylaxis of migraine. Forty-nine patients with either classic or common migraine were treated with propranolol 160 mg/day for an average of six months. The first 30 of the patients to respond well to this treatment then participated in a double-blind cross-over trial with a placebo and propranolol. The mean frequency of headache attacks was significantly reduced by propranolol. None of the patients expressed a preference for placebo. Propranolol seems to be an effective prophylactic for common and classic migraine but the antimigraine properties of the various beta-blocking agents probably differ.